Administration of a single dose of<unk>  with rifampicin, a strong inducer of the enzyme CYP3A4, cuts the biological half-life and total exposure (AUC) of<unk>  in half, but has no relevant influence on highest concentrations in the blood. Combination with ketoconazole, a strong CYP3A4 inhibitor, has no relevant effects. The clinical significance of these findings is not known.
Tivozanib
Vatalanib
Pegaptanib
Pazopanib
Nintedanib
Abrocitinib
Gilteritinib
Erdafitinib